Last reviewed · How we verify
XNW5004 placebo; Chidamide
Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.
Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes. Used for Relapsed or refractory peripheral T-cell lymphoma, Relapsed or refractory cutaneous T-cell lymphoma.
At a glance
| Generic name | XNW5004 placebo; Chidamide |
|---|---|
| Sponsor | Evopoint Biosciences Inc. |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylases |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Histone deacetylases are enzymes that remove acetyl groups from histones, leading to chromatin compaction and reduced gene expression. By inhibiting these enzymes, chidamide promotes the expression of genes involved in cell cycle arrest and apoptosis, ultimately leading to the death of cancer cells.
Approved indications
- Relapsed or refractory peripheral T-cell lymphoma
- Relapsed or refractory cutaneous T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XNW5004 placebo; Chidamide CI brief — competitive landscape report
- XNW5004 placebo; Chidamide updates RSS · CI watch RSS
- Evopoint Biosciences Inc. portfolio CI